Welcome to our dedicated page for Cencora news (Ticker: COR), a resource for investors and traders seeking the latest updates and insights on Cencora stock.
Cencora, Inc. reports news around its role as a global pharmaceutical solutions organization that distributes branded, generic and specialty pharmaceuticals to pharmacies, hospital networks and healthcare providers. Company updates also cover commercialization services for pharmaceutical and medical-device manufacturers, specialty drug logistics through World Courier, animal health distribution through MWI Animal Health and international wholesale activity following the Alliance Healthcare acquisition.
Recurring developments include fiscal operating results, gross profit drivers, LIFO effects, GLP-1 product mix and performance in U.S. Healthcare Solutions. News also covers completed acquisitions such as OneOncology and Retina Consultants of America, senior note financing, shareholder and governance matters, and executive leadership transitions.
Cencora (NYSE: COR) elected Ellen Cooper to its Board of Directors, effective January 20, 2026. Ms. Cooper is chairman, president and CEO of Lincoln Financial and became CEO in May 2022. Her background includes roles as Executive VP and Chief Investment Officer at Lincoln, Managing Director and Global Head of Insurance Strategy at Goldman Sachs Asset Management, Chief Risk Officer for AEGON Americas, and Principal at Ernst & Young.
She holds a BBA from Temple University and professional credentials including Fellow of the Society of Actuaries, Chartered Enterprise Risk Analyst, and Chartered Financial Analyst.
Cencora (NYSE: COR) will release its First Quarter Fiscal 2026 results on Wednesday, February 4, 2026 before the NYSE opens and will host a conference call at 8:30 a.m. ET the same day.
Management participants: Robert P. Mauch, President & Chief Executive Officer, and James F. Cleary, Executive Vice President & Chief Financial Officer. The live webcast and replay will be available at investor.cencora.com. Webcast replay will be posted about one hour after the call and will remain available for one year; telephonic replay will be available for seven days.
Cencora reports having 51,000+ employees worldwide and more than $300 billion in annual revenue; investors should check the investor website for updates and access details.
Cencora (NYSE: COR) agreed to acquire the remaining majority equity interests in OneOncology, valuing the platform at $7.4 billion enterprise and approximately $6.0 billion equity. Cencora will pay ~$3.6 billion to purchase shares and retire ~$1.3 billion of OneOncology corporate debt, for total cash consideration of ~$5.0 billion. The deal is expected to close by the end of Cencora's fiscal 2026 Q2, subject to customary conditions and regulatory approvals.
The transaction will be debt-funded; Cencora says it will prioritize deleveraging and maintain investment-grade ratings. Management paused share repurchases and expects the deal to be approximately EPS-neutral (adjusted) in the first 12 months. Cencora raised long-term guidance ranges for adjusted operating income (7–10%) and adjusted diluted EPS (10–14%), and reiterated fiscal 2026 consolidated guidance.
Cencora (NYSE: COR) reported fourth-quarter fiscal 2025 revenue of $83.7B, up 5.9% year‑over‑year, and fiscal 2025 revenue of $321.3B, up 9.3%. Fourth‑quarter GAAP diluted EPS was $(1.75) while adjusted diluted EPS was $3.84 (+15.0%). Fiscal year GAAP diluted EPS was $7.96 and adjusted diluted EPS was $16.00 (+16.3%).
The company cites the January 2025 acquisition of Retina Consultants of America (RCA) as a key driver, recorded goodwill impairments related to PharmaLex, plans $1B of U.S. distribution investments through 2030, and raised long‑term guidance expectations. The board approved a 9% quarterly dividend increase to $0.60 per share, payable Dec 1, 2025.
IntrinsiQ Specialty Solutions (NASDAQ:COR) announced expanded data capabilities on October 16, 2025 to deliver oncology biomarker data and enhanced therapeutic insights across oncology, retina and other therapeutic areas. Key goals are to enable precision medicine, help physicians tailor cancer therapies, and give manufacturers a fuller view of real-world utilization and adoption.
The offering combines biomarker data with physician and clinical care insights to support targeted outreach, education, and improved patient outcomes while leveraging Cencora's distribution and integrated specialty solutions.
Cencora (NYSE: COR) will release Fourth Quarter Fiscal 2025 results on Wednesday, November 5, 2025 prior to NYSE open and will host a conference call at 8:30 a.m. ET the same day.
Management on the call: Robert P. Mauch (CEO) and James F. Cleary (CFO). The live webcast and replay will be available at investor.cencora.com. Teleconference access and replay phone numbers and access codes are provided for domestic and international callers.
Cencora (NYSE: COR) has appointed Lead Independent Director D. Mark Durcan as Chairman of the Board of Directors, effective October 1, 2025. Durcan succeeds Steven H. Collis, who served as Chairman since 2016 and previously as CEO from 2011 to 2024.
Durcan brings significant experience as the former CEO of Micron Technology (2012-2017) and has served on Cencora's Board since 2015, becoming Lead Independent Director in 2023. He currently serves as a director of ASML Holding NV and on Rice University's Board of Trustees.
Cencora (NYSE: COR) reported strong Q3 fiscal 2025 results with revenue reaching $80.7 billion, up 8.7% year-over-year. The company achieved GAAP diluted EPS of $3.52 and adjusted diluted EPS of $4.00, marking a 19.8% increase from the prior year.
Key highlights include the successful integration of Retina Consultants of America (RCA) acquired in January 2025, strong performance in U.S. Healthcare Solutions segment with 8.5% revenue growth, and International Healthcare Solutions segment showing 10.5% revenue growth. The company has raised its fiscal 2025 adjusted EPS guidance to $15.85-$16.00 from the previous $15.70-$15.95 range.
The Board declared a quarterly cash dividend of $0.55 per share, payable September 3, 2025, to stockholders of record as of August 15, 2025.
Cencora (NYSE: COR), a leading global pharmaceutical solutions organization ranked #10 on the Fortune 500, has scheduled its Third Quarter Fiscal 2025 earnings release for August 6, 2025, before the NYSE opening.
The company will host a conference call at 8:30 a.m. ET featuring CEO Robert P. Mauch and CFO James F. Cleary. The call will be accessible via webcast at investor.cencora.com and through telephone dial-in options. Replay options will be available through both webcast and telephone channels.
Cencora, with over $290 billion in annual revenue and 51,000+ worldwide team members, focuses on improving health outcomes through pharmaceutical solutions and market access optimization.
Cencora (NYSE: COR) has announced the election of Lori J. Ryerkerk to its Board of Directors, effective June 1, 2025. Ryerkerk, the former Chairman, President and CEO of Celanese, brings extensive experience in global supply chains and manufacturing operations. Her background includes over 25 years in leadership roles, notably as Executive Vice President of Global Manufacturing at Shell Downstream Inc. She currently serves on the boards of Eaton Corp. and Norfolk Southern. The appointment aligns with Cencora's strategy to strengthen its position as an end-to-end healthcare services provider.